116 related articles for article (PubMed ID: 16682193)
1. Discovery and SAR of 2-amino-5-(thioaryl)thiazoles as potent and selective Itk inhibitors.
Das J; Furch JA; Liu C; Moquin RV; Lin J; Spergel SH; McIntyre KW; Shuster DJ; O'Day KD; Penhallow B; Hung CY; Doweyko AM; Kamath A; Zhang H; Marathe P; Kanner SB; Lin TA; Dodd JH; Barrish JC; Wityak J
Bioorg Med Chem Lett; 2006 Jul; 16(14):3706-12. PubMed ID: 16682193
[TBL] [Abstract][Full Text] [Related]
2. Discovery and SAR of 2-amino-5-[(thiomethyl)aryl]thiazoles as potent and selective Itk inhibitors.
Das J; Liu C; Moquin RV; Lin J; Furch JA; Spergel SH; Doweyko AM; McIntyre KW; Shuster DJ; O'Day KD; Penhallow B; Hung CY; Kanner SB; Lin TA; Dodd JH; Barrish JC; Wityak J
Bioorg Med Chem Lett; 2006 May; 16(9):2411-5. PubMed ID: 16481166
[TBL] [Abstract][Full Text] [Related]
3. Selective Itk inhibitors block T-cell activation and murine lung inflammation.
Lin TA; McIntyre KW; Das J; Liu C; O'Day KD; Penhallow B; Hung CY; Whitney GS; Shuster DJ; Yang X; Townsend R; Postelnek J; Spergel SH; Lin J; Moquin RV; Furch JA; Kamath AV; Zhang H; Marathe PH; Perez-Villar JJ; Doweyko A; Killar L; Dodd JH; Barrish JC; Wityak J; Kanner SB
Biochemistry; 2004 Aug; 43(34):11056-62. PubMed ID: 15323564
[TBL] [Abstract][Full Text] [Related]
4. Discovery, SAR and X-ray structure of 1H-benzimidazole-5-carboxylic acid cyclohexyl-methyl-amides as inhibitors of inducible T-cell kinase (Itk).
Moriarty KJ; Takahashi H; Pullen SS; Khine HH; Sallati RH; Raymond EL; Woska JR; Jeanfavre DD; Roth GP; Winters MP; Qiao L; Ryan D; DesJarlais R; Robinson D; Wilson M; Bobko M; Cook BN; Lo HY; Nemoto PA; Kashem MA; Wolak JP; White A; Magolda RL; Tomczuk B
Bioorg Med Chem Lett; 2008 Oct; 18(20):5545-9. PubMed ID: 18819799
[TBL] [Abstract][Full Text] [Related]
5. 5-Aminomethyl-1H-benzimidazoles as orally active inhibitors of inducible T-cell kinase (Itk).
Winters MP; Robinson DJ; Khine HH; Pullen SS; Woska JR; Raymond EL; Sellati R; Cywin CL; Snow RJ; Kashem MA; Wolak JP; King J; Kaplita PV; Liu LH; Farrell TM; DesJarlais R; Roth GP; Takahashi H; Moriarty KJ
Bioorg Med Chem Lett; 2008 Oct; 18(20):5541-4. PubMed ID: 18823779
[TBL] [Abstract][Full Text] [Related]
6. Discovery of potent inhibitors of interleukin-2 inducible T-cell kinase (ITK) through structure-based drug design.
Cook BN; Bentzien J; White A; Nemoto PA; Wang J; Man CC; Soleymanzadeh F; Khine HH; Kashem MA; Kugler SZ; Wolak JP; Roth GP; De Lombaert S; Pullen SS; Takahashi H
Bioorg Med Chem Lett; 2009 Feb; 19(3):773-7. PubMed ID: 19111460
[TBL] [Abstract][Full Text] [Related]
7. Novel and potent inhibitors of stearoyl-CoA desaturase-1. Part I: Discovery of 3-(2-hydroxyethoxy)-4-methoxy-N-[5-(3-trifluoromethylbenzyl)thiazol-2-yl]benzamide.
Uto Y; Ogata T; Harada J; Kiyotsuka Y; Ueno Y; Miyazawa Y; Kurata H; Deguchi T; Watanabe N; Takagi T; Wakimoto S; Okuyama R; Abe M; Kurikawa N; Kawamura S; Yamato M; Osumi J
Bioorg Med Chem Lett; 2009 Aug; 19(15):4151-8. PubMed ID: 19540759
[TBL] [Abstract][Full Text] [Related]
8. Discovery and structure-activity relationship of 3-aminopyrid-2-ones as potent and selective interleukin-2 inducible T-cell kinase (Itk) inhibitors.
Charrier JD; Miller A; Kay DP; Brenchley G; Twin HC; Collier PN; Ramaya S; Keily SB; Durrant SJ; Knegtel RM; Tanner AJ; Brown K; Curnock AP; Jimenez JM
J Med Chem; 2011 Apr; 54(7):2341-50. PubMed ID: 21391610
[TBL] [Abstract][Full Text] [Related]
9. Discovery of 2-amino-heteroaryl-benzothiazole-6-anilides as potent p56(lck) inhibitors.
Das J; Moquin RV; Lin J; Liu C; Doweyko AM; DeFex HF; Fang Q; Pang S; Pitt S; Shen DR; Schieven GL; Barrish JC; Wityak J
Bioorg Med Chem Lett; 2003 Aug; 13(15):2587-90. PubMed ID: 12852972
[TBL] [Abstract][Full Text] [Related]
10. Structure-based design and synthesis of potent benzothiazole inhibitors of interleukin-2 inducible T cell kinase (ITK).
MacKinnon CH; Lau K; Burch JD; Chen Y; Dines J; Ding X; Eigenbrot C; Heifetz A; Jaochico A; Johnson A; Kraemer J; Kruger S; Krülle TM; Liimatta M; Ly J; Maghames R; Montalbetti CA; Ortwine DF; Pérez-Fuertes Y; Shia S; Stein DB; Trani G; Vaidya DG; Wang X; Bromidge SM; Wu LC; Pei Z
Bioorg Med Chem Lett; 2013 Dec; 23(23):6331-5. PubMed ID: 24138940
[TBL] [Abstract][Full Text] [Related]
11. Molecular design, synthesis, and structure-Activity relationships leading to the potent and selective p56(lck) inhibitor BMS-243117.
Das J; Lin J; Moquin RV; Shen Z; Spergel SH; Wityak J; Doweyko AM; DeFex HF; Fang Q; Pang S; Pitt S; Shen DR; Schieven GL; Barrish JC
Bioorg Med Chem Lett; 2003 Jul; 13(13):2145-9. PubMed ID: 12798323
[TBL] [Abstract][Full Text] [Related]
12. Discovery and optimization of indazoles as potent and selective interleukin-2 inducible T cell kinase (ITK) inhibitors.
Pastor RM; Burch JD; Magnuson S; Ortwine DF; Chen Y; De La Torre K; Ding X; Eigenbrot C; Johnson A; Liimatta M; Liu Y; Shia S; Wang X; Wu LC; Pei Z
Bioorg Med Chem Lett; 2014 Jun; 24(11):2448-52. PubMed ID: 24767842
[TBL] [Abstract][Full Text] [Related]
13. Structure-activity relationship study of a novel necroptosis inhibitor, necrostatin-7.
Zheng W; Degterev A; Hsu E; Yuan J; Yuan C
Bioorg Med Chem Lett; 2008 Sep; 18(18):4932-5. PubMed ID: 18768316
[TBL] [Abstract][Full Text] [Related]
14. Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors.
Rewcastle GW; Murray DK; Elliott WL; Fry DW; Howard CT; Nelson JM; Roberts BJ; Vincent PW; Showalter HD; Winters RT; Denny WA
J Med Chem; 1998 Feb; 41(5):742-51. PubMed ID: 9513602
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of the IL-2-inducible tyrosine kinase (Itk) activity: a new concept for the therapy of inflammatory skin diseases.
von Bonin A; Rausch A; Mengel A; Hitchcock M; Krüger M; von Ahsen O; Merz C; Röse L; Stock C; Martin SF; Leder G; Döcke WD; Asadullah K; Zügel U
Exp Dermatol; 2011 Jan; 20(1):41-7. PubMed ID: 21158938
[TBL] [Abstract][Full Text] [Related]
16. 5-Aminomethylbenzimidazoles as potent ITK antagonists.
Riether D; Zindell R; Kowalski JA; Cook BN; Bentzien J; Lombaert SD; Thomson D; Kugler SZ; Skow D; Martin LS; Raymond EL; Khine HH; O'Shea K; Woska JR; Jeanfavre D; Sellati R; Ralph KL; Ahlberg J; Labissiere G; Kashem MA; Pullen SS; Takahashi H
Bioorg Med Chem Lett; 2009 Mar; 19(6):1588-91. PubMed ID: 19246196
[TBL] [Abstract][Full Text] [Related]
17. Covalent modification of cyclooxygenase-2 (COX-2) by 2-acetoxyphenyl alkyl sulfides, a new class of selective COX-2 inactivators.
Kalgutkar AS; Kozak KR; Crews BC; Hochgesang GP; Marnett LJ
J Med Chem; 1998 Nov; 41(24):4800-18. PubMed ID: 9822550
[TBL] [Abstract][Full Text] [Related]
18. Optimisation of ITK inhibitors through successive iterative design cycles.
Herdemann M; Weber A; Jonveaux J; Schwoebel F; Stoeck M; Heit I
Bioorg Med Chem Lett; 2011 Mar; 21(6):1852-6. PubMed ID: 21316219
[TBL] [Abstract][Full Text] [Related]
19. Identification of potent ITK inhibitors through focused compound library design including structural information.
Herdemann M; Heit I; Bosch FU; Quintini G; Scheipers C; Weber A
Bioorg Med Chem Lett; 2010 Dec; 20(23):6998-7003. PubMed ID: 20965724
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of p56(lck) tyrosine kinase by isothiazolones.
Trevillyan JM; Chiou XG; Ballaron SJ; Tang QM; Buko A; Sheets MP; Smith ML; Putman CB; Wiedeman P; Tu N; Madar D; Smith HT; Gubbins EJ; Warrior UP; Chen YW; Mollison KW; Faltynek CR; Djurić SW
Arch Biochem Biophys; 1999 Apr; 364(1):19-29. PubMed ID: 10087161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
